B cell activating factor (BAFF) and BAFF receptors: fakes and facts. (28th September 2017)

• Record Type: Journal Article
• Authors: Ferraccioli, G; Gremese, E
• Is Part Of: Clinical and experimental immunology. Volume 190:Number 3(2017:Dec.)
• Page Start: 291
• Page End: 292
• Publication Date: 2017-09-28
• Subjects: B cell depletion therapy -- BAFF -- BAFF receptors -- BR3 -- rheumatoid arthritis; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.13039
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: Analysis of B cell activating factor (BAFF) receptors before and after B cell depletion therapy (BCDT) might offer a clue to the understanding of whether some B cell subsets may represent useful biomarkers of biological and clinical responses. Among the BAFF receptors in a cohort of rheumatoid arthritis (RA) patients, the AA have shown, by fluorescence activated cell sorter (FACS) analysis of median fluorescence intensity (MFI), that transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA) do not change, whereas the most important, BAFF receptor 3 (BR3), appears to be decreased before as well as after BCDT in all B cell subsets but not in plasmablasts, the most important subset, depleted by BCDT.